A5024949068- Acute Myeloid Leukemia Research
- Urinary and Genital Oncology Studies
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Venetoclax (VEN) plus HMA regimen is the standard of care for older adults with AML, however it associated significant myelosuppression and complications, potentially limiting its use in very old. We performed a multi-center retrospective analysis VEN-HMA treatment octo- nonagenarians to further understand tolerability, feasibility, dosing considerations, clinical efficacy this unique group. AML patients 80 years or who received between March 2015 April 2022 were reviewed. was determined by...
We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites 1-5) and 35 (76%) concurrent bone marrow involvement. Twenty (43%) highrisk genetic features according the European Leukemia Net 2022 classification. Twenty-nine (63%) were relapsed or refractory after intensive chemotherapy (CTX) including 13 (28%) prior allogeneic hematopoietic cell...